Press Releases

Date Title and Summary Additional Formats
Toggle Summary Xencor to Present at Upcoming Investor Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Feb. 28, 2024-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor
View HTML
Toggle Summary Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
-- Clinical development focus on high-potential XmAb ® T cell engagers and selective dual checkpoint inhibitor, vudalimab -- -- Vudalimab (PD-1 x CTLA-4) monotherapy generally well tolerated with encouraging clinical benefit for patients with high-risk mCRPC who have advanced beyond standard of
View HTML
Toggle Summary Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
PASADENA, Calif. --(BUSINESS WIRE)--Feb. 20, 2024-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth
View HTML
Toggle Summary Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 3, 2024-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat , Ph.D., president and chief executive
View HTML
Toggle Summary Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 2, 2024-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Dane Leone , CFA, has joined Xencor as senior vice
View HTML
Toggle Summary Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 21, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced that company management will present at the
View HTML
Toggle Summary Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 7, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the sale of portions of financial interests from Alexion
View HTML
Toggle Summary Xencor Reports Third Quarter 2023 Financial Results
-- Royalty Transaction Generates $215 Million Upfront -- -- Management to Host Conference Call at 4:30 p.m. ET Today -- PASADENA, Calif. --(BUSINESS WIRE)--Nov. 7, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the
View HTML
Toggle Summary Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 3, 2023-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented data from multiple preclinical-stage XmAb ® programs at the
View HTML
Toggle Summary Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023
PASADENA, Calif. --(BUSINESS WIRE)--Oct. 31, 2023-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release third quarter 2023 financial results after
View HTML